September 14, 2016 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a manufacturing alliance today with Omnia Biologics to clone and produce alpha-cobratoxin for the production of RPI-78M for upcoming clinical trials in Pediatric Multiple Sclerosis.
"Pediatric Multiple Sclerosis is a pressing and unmet medical need,” commented Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “While it is distinct from the adult form of the disease, there are no drugs approved for the treatment of Pediatric MS. These children have no other option than to rely on off label use of adult MS drugs to control their disease," he continued. "Based on our pre-clinical and open-label studies, we believe that RPI-78M has the ability to successfully navigate the approval process. We are now working with Omnia to scale up drug manufacturing in preparation for the upcoming clinical trials," he concluded.
The Company previously announced that they had been granted Orphan Designation by the US-Food and Drug Administration (FDA) for the treatment of Pediatric Multiple Sclerosis with RPI-78M. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Omnia Biologics will clone the alpha-cobratoxin gene as the raw material for the production of the drug, RPI-78M. They will also produce the purified clinical trial materials for the proposed studies in their cGMP manufacturing facilities located in Rockville, Maryland. Additionally, Omnia will provide process and assay development services that will be necessary as the drug moves through the FDA approval process.
RPI-78M was originally derived from an extract of cobra venom and is an antagonist of the nicotinic acetylcholine receptor. The drug has a remarkably low toxicity with a very large therapeutic window. Scientific publications have demonstrated that native and modified neurotoxins can protect nerve cells from early cell death. Furthermore, it is expected that RPI-78M may be beneficial in neuromuscular disorders where the activity of nicotinic acetylcholine receptor has been compromised. The proprietary technology is covered by patents describing the application and use of RPI-78M in the treatment of autoimmune diseases.
About Omnia Biologics
Omnia Biologics, located in Rockville, MD, offers an array of manufacturing and process development services for companies engaged in the development of novel biologics. They have experience in many of these areas – from preclinical gene therapeutics through commercial recombinant proteins – giving Omnia a unique and specialized approach for developing manufacturing processes. The company has both non-GMP and GMP facilities for process development through Phase I/II manufacturing.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The alliance with Omnia Biologics should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.